journal
MENU ▼
Read by QxMD icon Read
search

Clinical Genitourinary Cancer

journal
https://www.readbyqxmd.com/read/28720439/outcomes-of-patients-with-long-term-treatment-response-to-vascular-endothelial-growth-factor-targeted-therapy-for-metastatic-renal-cell-cancer
#1
Tomas Buchler, Alexandr Poprach, Zbynek Bortlicek, Radek Lakomy, Renata Chloupková, Rostislav Vyzula, Milada Zemanova, Katerina Kopeckova, Marek Svoboda, Ondrej Slaby, Igor Kiss, Hana Studentova, Jana Hornova, Ondrej Fiala, Jindrich Kopecky, Jindrich Finek, Ladislav Dusek, Bohuslav Melichar
BACKGROUND: Although targeted therapies with inhibitors of the vascular endothelial growth factor (VEGF) are the mainstay of treatment for metastatic renal cell carcinoma, there are limited data on the outcome of patients with long-term response to this treatment. PATIENTS AND METHODS: In a retrospective, registry-based study, patients continuously treated with first-line anti-VEGF agents for at least 24 months were included. In total, 219 patients had evaluable data and were included in the outcome analysis...
June 29, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28711490/long-term-response-to-sunitinib-treatment-in-metastatic-renal-cell-carcinoma-a-pooled-analysis-of-clinical-trials
#2
Nizar M Tannir, Robert A Figlin, Martin E Gore, M Dror Michaelson, Robert J Motzer, Camillo Porta, Brian I Rini, Caroline Hoang, Xun Lin, Bernard Escudier
BACKGROUND: We characterized clinical outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib who were long-term responders (LTRs), defined as patients having progression-free survival (PFS) > 18 months. PATIENTS AND METHODS: A retrospective analysis of data from 5714 patients with mRCC treated with sunitinib in 8 phase II/III clinical trials and the expanded access program. Duration on-study and objective response rate (ORR) were compared between LTRs and patients with PFS ≤ 18 months ("others")...
June 20, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28729067/real-world-characteristics-and-outcomes-of-patients-with-metastatic-castration-resistant-prostate-cancer-receiving-chemotherapy-versus-androgen-receptor-targeted-therapy-after-failure-of-first-line-androgen-receptor-targeted-therapy-in-the-community-setting
#3
William K Oh, Raymond Miao, Francis Vekeman, Jennifer Sung, Wendy Y Cheng, Marjolaine Gauthier-Loiselle, Ravinder Dhawan, Mei Sheng Duh
BACKGROUND: In metastatic castration-resistant prostate cancer (mCRPC), optimal treatment sequences are unknown. We assessed second-line taxane (TT) versus androgen receptor-targeted therapy (ART), after initial ART failure, in United States oncology community practices. PATIENTS AND METHODS: Using electronic medical records, patients with mCRPC receiving first-line ART and second-line therapy (TT, ART) were identified. Response and overall survival (OS) were evaluated from second-line therapy initiation...
June 19, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28694147/predictive-and-prognostic-value-of-preoperative-thrombocytosis-in-upper-tract-urothelial-carcinoma
#4
Beat Foerster, Marco Moschini, Mohammad Abufaraj, Francesco Soria, Kilian M Gust, Morgan Rouprêt, Pierre I Karakiewicz, Alberto Briganti, Michael Rink, Luis Kluth, Romain Mathieu, Vitaly Margulis, Yair Lotan, Atiqullah Aziz, Hubert John, Shahrokh F Shariat
PURPOSE: The purpose of this study was to evaluate the predictive and prognostic role of preoperative thrombocytosis (TC) in upper tract urothelial carcinoma (UTUC) after radical nephroureterectomy (RNU) in a large multi-institutional cohort of patients. METHODS: Records of 2492 patients undergoing RNU for non-metastatic UTUC between 1990 and 2008 were retrospectively analyzed. Preoperative TC was defined as a platelet count > 400 × 10(9)/L, irrespective of gender type...
June 19, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28668277/a-phase-ii-trial-of-aezs-108-in-castration-and-taxane-resistant-prostate-cancer
#5
Steven S Yu, Kanthi Athreya, Stephen V Liu, Andrew V Schally, Denice Tsao-Wei, Susan Groshen, David I Quinn, Tanya B Dorff, Shigang Xiong, Jurgen Engel, Jacek Pinski
BACKGROUND: AEZS-108 (zoptarelin doxorubicin) is a cytotoxic hybrid molecule consisting of doxorubicin covalently coupled with a luteinizing hormone-releasing hormone (LHRH) analogue, which selectively targets doxorubicin to tumor cells expressing LHRH receptors. We report the clinical efficacy of AEZS-108 in a phase II trial in men with metastatic castrate-resistant prostate cancer who had disease progression after taxane-based chemotherapy. PATIENTS AND METHODS: Patients received AEZS-108 210 mg/m(2) intravenously every 3 weeks...
June 8, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28666689/optimum-tools-for-predicting-clinical-outcomes-in-prostate-cancer-patients-undergoing-radical-prostatectomy-a-systematic-review-of-prognostic-accuracy-and-validity
#6
REVIEW
Jared M Campbell, Elspeth Raymond, Michael E O'Callaghan, Andrew D Vincent, Kerri R Beckmann, David Roder, Sue Evans, John McNeil, Jeremy Millar, John Zalcberg, Martin Borg, Kim L Moretti
Prostate cancer is a heterogeneous disease whose therapies frequently have adverse effects. Informed patient counseling regarding likely clinical outcomes is therefore important. In this systematic review we aimed to identify all external validations of tools that are used to predict clinical outcomes in patients undergoing radical prostatectomy and evaluate which are optimum for clinical implementation. PubMed and EMBASE were searched from 2007 to 2016. Search terms related to the inclusion criteria were: prostate cancer, clinical outcomes, radical prostatectomy, and prognosis...
June 8, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28673798/rapid-response-to-nivolumab-in-a-patient-with-sarcomatoid-transformation-of-chromophobe-renal-cell-carcinoma
#7
Keren Rouvinov, Lidia Osyntsov, Ruthy Shaco-Levy, Nina Baram, Samuel Ariad, Wilmosh Mermershtain
No abstract text is available yet for this article.
June 3, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28655452/high-dose-abiraterone-acetate-in-men-with-castration-resistant-prostate-cancer
#8
Terence W Friedlander, Julie N Graff, Kreshnik Zejnullahu, Archana Anantharaman, Li Zhang, Rosa Paz, Gayatri Premasekharan, Carly Russell, Yong Huang, Won Kim, Rahul R Aggarwal, Amy M Lin, Lawrence Fong, Joshi J Alumkal, Tomasz M Beer, Nima Sharifi, Mohammad Alyamani, Ryan Dittamore, Eric J Small, Pamela L Paris, Charles J Ryan
BACKGROUND: Abiraterone acetate (AA) inhibits androgen biosynthesis and prolongs survival in men with metastatic castration-resistant prostate cancer (mCRPC) when combined with prednisone (P). Resistance to therapy remains incompletely understood. In this open-label, single-arm, multicenter phase II study we investigated the clinical benefit of increasing the dose of AA at the time of resistance to standard-dose therapy. PATIENTS AND METHODS: Eligible patients had progressive mCRPC and started AA 1000 mg daily and P 5 mg twice daily...
June 3, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28645483/chemosensitivity-of-immature-teratoma-in-a-man
#9
Alvin S Wong, Kian-Tai Chong, Thomas P Thamboo
No abstract text is available yet for this article.
June 3, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28669704/low-pressure-robot-assisted-radical-prostatectomy-with-the-airseal-system-at-olv-hospital-results-from-a-prospective-study
#10
Sabrina La Falce, Giacomo Novara, Giorgio Gandaglia, Paolo Umari, Geert De Naeyer, Frederiek D'Hondt, Jean Beresian, Rik Carette, Martin Penicka, Yujiing Mo, Geert Vandenbroucke, Alexandre Mottrie
BACKGROUND: Limited studies examined effects of pneumoperiotneum during robot-assisted radical prostatectomy (RARP) and with AirSeal. The aim of this study was to assess the effect on hemodynamics of a lower pressure pneumoperitoneum (8 mmHg) with AirSeal, during RARP in steep Trendelenburg 45° (ST). MATERIALS AND METHODS: This is an institutional review board-approved, prospective, interventional, single-center study including patients treated with RARP at OLV Hospital by one extremely experienced surgeon (July 2015-February 2016)...
June 2, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28673797/management-of-clinical-stage-i-nonseminomatous-germ-cell-testicular-tumors-a-25-year-single-center-experience
#11
Martina Ondrusova, Iveta Waczulikova, Viera Lehotska, Tomas Zeleny, Dalibor Ondrus
BACKGROUND: Surveillance after orchiectomy alone has become popular in the management of clinical stage I nonseminomatous germ cell testicular tumors (CSI NSGCTT). Efforts to identify patients at high risk of disease progression led to a search for risk factors in CSI NSGCTT. The aim of this study was to analyze a 25-year single-center experience with risk-adapted therapeutic approaches-active surveillance (AS) versus adjuvant chemotherapy (ACT). PATIENTS AND METHODS: From January 1992 to January 2017, a total of 485 patients with CSI NSGCTT were stratified into the AS group (low-risk patients) and the ACT group (high-risk patients)...
June 1, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28697982/prostate-cancer-screening-in-a-new-era-of-genetics
#12
Heather H Cheng, Colin C Pritchard, Bruce Montgomery, Daniel W Lin, Peter S Nelson
Men who inherit pathogenic germline mutations in BRCA2 and BRCA1 are at increased risk of developing aggressive prostate cancer, and those with germline mutations in other DNA repair genes such as ATM, CHEK2, and MSH2/MSH6 may also have increased risks. Although clinically important, there is lack of specific guidance regarding management strategies for men at increased risk owing to germline mutation status or family history of aggressive prostate cancer. We review prostate cancer genetic risk factors and the ongoing IMPACT (Identification of Men with a genetic predisposition to ProstAte Cancer: Targeted screening in BRCA1/2 mutation carriers and controls) screening study...
May 31, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28668276/a-walking-intervention-among-men-with-prostate-cancer-a-pilot-study
#13
Claire H Pernar, Katja Fall, Jennifer R Rider, Sarah C Markt, Hans-Olov Adami, Sven-Olof Andersson, Unnur Valdimarsdottir, Ove Andrén, Lorelei A Mucci
BACKGROUND: Men diagnosed with prostate cancer have increased risk for disease progression, cardiovascular events, and impairments in quality of life. This pilot study evaluated the feasibility of a randomized walking group intervention to improve quality of life, circulating biomarkers, and morbidity among men with newly diagnosed prostate cancer. METHODS: Men were recruited at Örebro University Hospital, Sweden, and randomized to an 11-week walking group intervention (n = 21) or usual care (n = 20)...
May 31, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28645482/proton-pump-inhibitors-and-survival-outcomes-in-patients-with-metastatic-renal-cell-carcinoma
#14
Aly-Khan A Lalani, Rana R McKay, Xun Lin, Ronit Simantov, Marina D Kaymakcalan, Toni K Choueiri
INTRODUCTION: Proton pump inhibitors (PPIs) are potent inhibitors of gastric acid secretion and can affect the optimal absorption of concomitant oral medications, such as vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors (TKIs). The purpose of this study was to investigate the effect of PPI use on survival in metastatic renal cell carcinoma (mRCC) patients treated in the targeted therapy era. MATERIALS AND METHODS: We conducted a pooled analysis of mRCC patients treated in phase II and III clinical trials...
May 31, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28690098/m%C3%A3-llerian-adenosarcoma-of-the-urinary-bladder-clinicopathologic-and-immunohistochemical-features-with-novel-genetic-aberrations
#15
Joseph Sanfrancesco, Sean R Williamson, Jennifer B Kum, Shaobo Zhang, Mingsheng Wang, Antonio Lopez-Beltran, Rodolfo Montironi, Thomas A Gardner, Liang Cheng
BACKGROUND: Müllerian adenosarcoma is a biphasic neoplasm most commonly occurring in the uterus and less frequently of the ovary. It has been rarely described to occur in other sites such as peritoneum and liver. PATIENTS AND METHODS: In this study, we report the clinicopathologic, immunohistochemical and molecular features of a primary Müllerian adenosarcoma of the urinary bladder in a 62-year-old woman. To our knowledge, this is the first report of detailed pathologic characterization of Müllerian adenosarcoma primary to the urinary bladder in the literature...
May 25, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28645484/immune-check-point-inhibition-in-sarcomatoid-renal-cell-carcinoma-a-new-treatment-paradigm
#16
Ruben Raychaudhuri, Matthew J Riese, Kathryn Bylow, John Burfeind, Alexander C Mackinnon, Parag P Tolat, Kenneth A Iczkowski, Deepak Kilari
No abstract text is available yet for this article.
May 25, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28624320/prognostic-value-of-the-vhl-hif-1%C3%AE-and-vegf-signaling-pathway-and-associated-mapk-erk1-2-and-erk5-pathways-in-clear-cell-renal-cell-carcinoma-a-long-term-study
#17
Antonio S Salinas-Sánchez, Leticia Serrano-Oviedo, Syongh Y Nam-Cha, Olga Roche-Losada, Ricardo Sánchez-Prieto, José M Giménez-Bachs
BACKGROUND: The prognostic value of molecular markers in renal cell carcinoma has been investigated in several studies. Although their value is still not confirmed, various proteins are important. We describe the effect on long-term survival of the status of the von Hippel-Lindau (VHL) hypoxia-inducible factor 1-α (HIF1-α) signaling pathway as well as associated mitogen-activated protein kinase (extracellular signal-regulated kinase [ERK]1/2 and ERK5). PATIENTS AND METHODS: A prospective, longitudinal cohort study was conducted with 50 patients diagnosed with clear-cell renal cell carcinoma to analyze VHL mutations and hypermethylation as well as VHL, HIF1-α, vascular endothelial growth factor (VEGF), ERK1/2, and ERK5 protein expression...
May 25, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28624319/the-efficacy-of-lenvatinib-and-everolimus-in-chromophobe-type-non-clear-cell-renal-cell-carcinoma-a-case-report-and-literature-review
#18
Candice Schwartz, Nicklas Pfanzelter, Timothy M Kuzel
No abstract text is available yet for this article.
May 25, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28606737/long-term-survival-in-a-patient-with-metastatic-ddr2-positive-adrenal-cortical-carcinoma
#19
Fadi Taza, Michal Chovanec, Noah Hahn, Costantine Albany
No abstract text is available yet for this article.
May 25, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28625691/a-case-of-locally-advanced-castration-resistant-prostate-cancer-with-remarkable-response-to-nivolumab
#20
Alina Basnet, Gaurav Khullar, Rohin Mehta, Namita Chittoria
No abstract text is available yet for this article.
May 24, 2017: Clinical Genitourinary Cancer
journal
journal
41208
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"